Federica Cecchi

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.

Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.

Journal: Journal of geriatric oncology

Published: March 23, 2023

Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.

Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 08, 2022

Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.

Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 24, 2021

Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?

Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?

Journal: Frontiers in oncology

Published: July 09, 2021

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma.

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma.

Journal: Frontiers in oncology

Published: June 30, 2021

Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.

Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.

Journal: European journal of clinical investigation

Published: March 15, 2021

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.

Journal: BMC cancer

Published: November 17, 2020

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient.

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient.

Journal: Frontiers in immunology

Published: July 02, 2020

Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.

Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.

Journal: Expert review of anticancer therapy

Published: April 25, 2020

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 29, 2020

Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1.

Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1.

Journal: Cancers

Published: March 24, 2020

Primary cutaneous melanoma: correlation between clinical and histologic aspects in a retrospective Italian study.

Primary cutaneous melanoma: correlation between clinical and histologic aspects in a retrospective Italian study.

Journal: Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia

Published: October 23, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026